Patients with HCC expressing higher IGF2BP3 showed worser overall survival (OS) as well as disease-free survival (DFS) than those expressing lower IGF2BP3 group (Figure 1A and Figure 1B). The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.